Autor(es): Bot Ilja; Blank Christian U.; Boogerd Willem; Brandsma Dieta

Resumo: Ipilimumab enhances the T lymphocyte mediated immune response to both tumour cells and healthy tissue, improving survival in patients with metastatic melanoma but also leads to more immune-related adverse events (irAEs) than previously used treatments, such as dacarbazine. We present three patients with neurological irAEs from ipilimumab treatment: hypophysitis, meningitis and Guillain-Barré syndrome. Once an irAE occurs, ipilimumab should be stopped and corticosteroids started. Usually, ipilimumab-induced irAE symptoms improve within days to weeks, but can be life-threatening if unrecognised.

Palavras-Chave: NEUROONCOLOGY, NEUROPHARMACOLOGY

Imprenta: Practical Neurology, v. 13, n. 4, p. 278-280, 2013

Identificador do objeto digital: 10.1136/practneurol-2012-000447

Descritores: Guillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Immune response ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Immunology

Data de publicação: 2013

INDICADORES

ACESSO